Valgimigli’s research has influenced both European and USA clinical practice guidelines in multiple aspects. Impacting the coronary stent selection, regimens of various anti-thrombotic drugs & access site choice during coronary intervention. Initially starting as member/reviewer of multiple ESC guidelines task forces, he then acted as chair of the European update guidelines on DAPT. He acted as PI for multiple investigator initiated global randomized studies in interventional cardiology. Studies such as STRATEGY, ADVANCE, MULTISTRATEGY, 3T/2R, PRODIGY, Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS), the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX), GLOBAL LEADERS and HI-TECH.